Skip to main content

Table 4 Post-transplantation engraftment and responses in 39 patients with high-risk non-Hodgkin’s lymphoma

From: Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma


R-CHOP (n = 14)

CHOP (n = 25)

P value

Time from APBSC infusion to WBC engraftment (days)a

11 (9–13)

11 (8–14)


Time from APBSC infusion to PLT engraftment (days)a

12.5 (7–18)

12.0 (9–32)


Duration of rhG-CSF support from APBSC infusion to engraftment (days)a

8.5 (4–12)

7.0 (3–25)


CR for B-cell lymphoma [cases (%)]b

14 (100)

4 (50)


  1. APBSC autologous peripheral blood stem cells, rhG-CSF recombinant human granulocyte colony-stimulating factor; CR, complete response. Other abbreviations as in Tables 1, 2 and 3
  2. aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses
  3. bAll the 14 patients in R-CHOP group and 8 patients in CHOP group had B-cell lymphoma